SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-071962
Filing Date
2022-03-10
Accepted
2022-03-10 16:16:21
Documents
15
Period of Report
2022-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d327084d8k.htm   iXBRL 8-K 25669
2 EX-99.1 d327084dex991.htm EX-99.1 19533
6 GRAPHIC g327084g0310234855175.jpg GRAPHIC 2223
7 GRAPHIC g327084g0311000435196.jpg GRAPHIC 2204
  Complete submission text file 0001193125-22-071962.txt   184091

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20220310.xsd EX-101.SCH 2885
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20220310_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20220310_pre.xml EX-101.PRE 11281
9 EXTRACTED XBRL INSTANCE DOCUMENT d327084d8k_htm.xml XML 3396
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 22729243
SIC: 8071 Services-Medical Laboratories